Floatz logo

Arginine Butyrate

Epstein-Barr Virus-Associated Lymphoproliferative Disorder

HemaQuest Pharmaceuticals Inc.UNKNOWNPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Epstein-Barr Virus-Associated Lymphoproliferative Disorder cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB
Valganciclovir
Viracta Therapeutics, Inc.
Phase 2B
Adriamycin
University of Miami
Phase 2CCC
Hydroxyurea
University of Miami
Phase 2CCC
Rituximab
University of Miami
Phase 2CCC

View all 17 →

Same molecule, other indications

Arginine Butyrate is also rated in:

beta thalassemiaDormant
B
Indicative · Phase 2
57 / 100
View asset →
sickle cell diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →
lymphoproliferative syndromeDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →